Barba 2003.

Study characteristics
Methods	Trial design: randomised double‐blind, multicentre, parallel study Trial registration number: not reported Country: Mexico Outpatient or hospital, date trial conducted: not reported Duration of trial participation: 3 weeks Inclusion criteria: · Paediatric patients (aged 3 months to 18 years) with mild‐to‐moderate AD of the face Exclusion criteria: not reported Additional design details: none
Participants	Total number randomised: 114 participants (76 to apply the intervention and 38 to apply the vehicle cream) Age: 3 months to 18 years Sex, ethnicity, duration of eczema: not reported Severity of eczema: mild‐to‐moderate Body site: face Number of withdrawals: 5/76 in the pimecrolimus group and 3/38 in the vehicle group did not complete. No reasons provided Notes: none
Interventions	Run‐in details: not reported Intervention: pimecrolimus 1% cream used not specified for 21 days Concurrent treatment: not reported Other key information: none Comparator: vehicle cream used not specified for 21 days Concurrent treatment: not reported Other key information: none Concurrent treatments received alongside both intervention and comparator: none Notes: none
Outcomes	· Facial IGA at three weeks · EASI at three weeks · Pruritis at three weeks · Patient assessment of good or complete control at three weeks · AE at three weeks
Notes	Funding source: not reported Declarations of interest: not declared Original language of publication: English Other: one